Tafoxiparin for Spontaneous Labor Onset
Summary
The USPTO has granted Patent US12611423B2 to DILAFOR AB for tafoxiparin as a medical compound for inducing spontaneous labor onset in term pregnant women. The patent covers administration of tafoxiparin at a daily dose of 30-320 mg. The patent contains 22 claims and lists Lena Degling-Wikingsson and Gunvor Ekman-Ordeberg as inventors.
“The present invention is directed to tafoxiparin for use in the spontaneous onset of labor in a term pregnant woman, wherein tafoxiparin is administered in a daily dose of 30-320 mg per day.”
About this source
USPTO classification A61P covers the therapeutic use of compounds: indications like cancer, inflammation, cardiovascular disease, CNS disorders, and rare diseases. Every patent grant in A61P lands in this feed, around 190 a month, with the patent number, title, applicant, inventor names, and abstract. A61P grants are frequently co-classified with composition-of-matter patents, so this feed is especially useful for mapping which chemical entities have secured both composition and method-of-use protection. Watch this if you run drug discovery, advise on biotech patent portfolios, scout in-licensing opportunities, or track antibody-drug conjugate and small-molecule oncology patent activity.
What changed
The USPTO granted Patent US12611423B2 for the pharmaceutical compound tafoxiparin (CPC: A61K 31/737, A61P 15/04) specifically directed to promoting spontaneous labor onset in term pregnant women. The patent specifies a daily dosage range of 30-320 mg. The filing date was May 2, 2023, with Application No. 18142121.
For DILAFOR AB, the patent grant establishes market exclusivity for this specific medical use of tafoxiparin through the patent term. Competing pharmaceutical manufacturers developing similar labor-induction therapies should note this issued patent and the defined dosage parameters when assessing freedom-to-operate for related compounds or indications.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Medical use of tafoxiparin
Grant US12611423B2 Kind: B2 Apr 28, 2026
Assignee
DILAFOR AB
Inventors
Lena Degling-Wikingsson, Gunvor Ekman-Ordeberg
Abstract
The present invention is directed to tafoxiparin for use in the spontaneous onset of labor in a term pregnant woman, wherein tafoxiparin is administered in a daily dose of 30-320 mg per day.
CPC Classifications
A61K 31/737 A61P 15/04
Filing Date
2023-05-02
Application No.
18142121
Claims
22
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.